Drug intelligence / Profile preview

C1C62-M3m4

Development stage: Unknown
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

C1C62-M3m4 is an investigational HIV-1 vaccine candidate designed to induce an immune response against the Human Immunodeficiency Virus type 1 (HIV-1). This vaccine aims to prevent or therapeutically manage HIV-1 infection by stimulating the host's immune system. It is currently undergoing clinical evaluation to assess its safety and immunogenicity in individuals with HIV-1 infection whose viral load is suppressed by antiretroviral therapy (ART). The development of C1C62-M3m4 is being led by the National Institute of Allergy and Infectious Diseases (NIAID).

Targets

HIV (HIV-1 enzymes)

Beyond the preview

Go deeper on C1C62-M3m4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C1C62-M3m4.

Explore the full profile